Neurodegeneration in the diabetic eye: New insights and therapeutic perspectives

Trends in Endocrinology and Metabolism

Volumn 25, Issue 1, 2014, Pages 23-33

  Simó, Rafael ^a   Hernández, Cristina ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Diabetic microangiopathy; Diabetic retinopathy; Eye drops; Neurodegeneration; Neuroprotection; Neurovascular unit

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CORTISTATIN; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTAMIC ACID; INTERPHOTORECEPTOR RETINOID BINDING PROTEIN; NITRIC OXIDE; PEGAPTANIB; PIGMENT EPITHELIUM DERIVED FACTOR; RANIBIZUMAB; REACTIVE OXYGEN METABOLITE; VASCULOTROPIN;

APOPTOSIS; BIOACCUMULATION; DIABETIC MICROANGIOPATHY; DIABETIC RETINOPATHY; DRUG TARGETING; ELECTRORETINOGRAM; GLIOSIS; HISTOPATHOLOGY; HUMAN; MORPHOLOGICAL TRAIT; NERVE DEGENERATION; NEUROPROTECTION; OXIDATIVE STRESS; PRIORITY JOURNAL; RETINA NERVE CELL; REVIEW; VISUAL IMPAIRMENT;

DIABETIC MICROANGIOPATHY; DIABETIC RETINOPATHY; EYE DROPS; NEURODEGENERATION; NEUROPROTECTION; NEUROVASCULAR UNIT;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; APOPTOSIS; DIABETIC RETINOPATHY; GLUTAMIC ACID; HUMANS; INFLAMMATION; MACULAR DEGENERATION; MICROCIRCULATION; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; RETINA; RETINAL VESSELS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84890989082     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2013.09.005     Document Type: Review

References (178)

1. Cheung N., et al. Diabetic retinopathy. Lancet 2010, 376:124-136.
2. Yau J.W., et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012, 35:556-564.
3. Lee L.J., et al. Direct and indirect costs among employees with diabetic retinopathy in the United States. Curr. Med. Res. Opin. 2008, 24:1549-1559.
4. Pelletier E.M., et al. Economic outcomes associated with microvascular complications of type 2 diabetes mellitus: results from a US claims data analysis. Pharmacoeconomics 2009, 27:479-490.
5. Heintz E., et al. Prevalence and healthcare costs of diabetic retinopathy: a population-based register study in Sweden. Diabetologia 2010, 53:2147-2154.
6. Whiting D.R., et al. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011, 94:311-321.
7. Mohamed, Q. et al. (2007) Management of diabetic retinopathy: a systematic review. JAMA 298,902-916.
8. Simó R., Hernández C. Advances in the medical treatment of diabetic retinopathy. Diabetes Care 2009, 32:1556-1562.
9. Do D.V., et al. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmol. 2013, 131:139-145.
10. Brown D.M., et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two Phase III trials: RISE and RIDE. Ophthalmology 2013, 120:2013-2022.
11. Bandello F., et al. New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel. Eye 2012, 26:485-493.
12. Zechmeister-Kos I., Huic M. Vascular endothelial growth factor inhibitors (anti-VEGF) in the management of diabetic macular oedema: a systematic review. Br. J. Ophthalmol. 2012, 96:167-178.
13. Diabetic Retinopathy Clinical Research Network, Elman M.J., et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology 2012, 119:2312-2318.
14. Simó R., Hernández C. Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia 2008, 51:1574-1580.
15. Virgili G., et al. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Cochrane Database Syst. Rev. 2012, 12:CD007419.
16. Joussen A.M., Joeres S. Benefits and limitations in vitreoretinal surgery for proliferative diabetic retinopathy and macular edema. Dev. Ophthalmol. 2007, 39:69-87.
17. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
18. Tang J., Kern T.S. Inflammation in diabetic retinopathy. Prog. Retin. Eye Res. 2011, 30:343-358.
19. Barber A.J., et al. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J. Clin. Invest. 1998, 102:783-791.
20. Lieth E., et al. Retinal neurodegeneration: early pathology in diabetes. Clin. Exp. Ophthalmol. 2000, 28:3-8.
21. Rungger-Brändle E., et al. Glial reactivity, an early feature of diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 2000, 4:1971-1980.
22. Lorenzi M., Gerhardinger C. Early cellular and molecular changes induced by diabetes in the retina. Diabetologia 2001, 44:791-804.
23. Barber A.J. A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27:283-290.
24. Simó R., Hernández C. Neurodegeneration is an early event in diabetic retinopathy: therapeutic implications. Br. J. Ophthalmol. 2012, 96:1285-1290.
25. Asnaghi V., et al. A role for the polyol pathway in the early neuroretinal apoptosis and glial changes induced by diabetes in the rat. Diabetes 2003, 52:506-511.
26. Antonetti D.A., et al. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes 2006, 55:2401-2411.
27. Fletcher E.L., et al. Neuronal and glial cell abnormality as predictors of progression of diabetic retinopathy. Curr. Pharm. Des. 2007, 13:2699-2712.
28. Kusari J., et al. Effect of memantine on neuroretinal function and retinal vascular changes of streptozotocin-induced diabetic rats. Invest. Ophthalmol. Vis. Sci. 2007, 48:5152-5159.
29. Imai H., et al. Neuroprotection for diabetic retinopathy. Dev. Ophthalmol. 2009, 44:56-68.
30. Feng Y., et al. Vasoregression linked to neuronal damage in the rat with defect of polycystin-2. PLoS ONE 2009, 4:e7328.
31. Kusari J., et al. Inhibition of vitreoretinal VEGF elevation and blood-retinal barrier breakdown in streptozotocin-induced diabetic rats by brimonidine. Invest. Ophthalmol. Vis. Sci. 2010, 51:1044-1051.
32. Feng Y., et al. Gene expression profiling of vasoregression in the retina-involvement of microglial cells. PLoS ONE 2011, 6:e16865.
33. Barber A.J., et al. The significance of vascular and neural apoptosis to the pathology of diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 2011, 52:1156-1163.
34. Kern T.S., Barber A.J. Retinal ganglion cells in diabetes. J. Physiol. 2008, 586:4401-4408.
35. van Dijk H.W., et al. Selective loss of inner retinal layer thickness in type 1 diabetic patients with minimal diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 2009, 50:3404-3409.
36. Lopes de Faria J.M., et al. Retinal nerve fibre layer loss in patients with type 1 diabetes mellitus without retinopathy. Br. J. Ophthalmol. 2002, 86:725-728.
37. van Dijk H.W., et al. Decreased retinal ganglion cell layer thickness in patients with type 1 diabetes. Invest. Ophthalmol. Vis. Sci. 2010, 51:3660-3665.
38. van Dijk H.W., et al. Association of visual function and ganglion cell layer thickness in patients with diabetes mellitus type 1 and no or minimal diabetic retinopathy. Vision Res. 2011, 28:244-248.
39. van Dijk H.W., et al. Early neurodegeneration in the retina of type 2 diabetic patients. Invest. Ophthalmol. Vis. Sci. 2012, 53:2715-2719.
40. Araszkiewicz A., et al. Neurodegeneration of the retina in type 1 diabetic patients. Pol. Arch. Med. Wewn. 2012, 122:464-470.
41. Carrasco E., et al. Lower somatostatin expression is an early event in diabetic retinopathy and is associated with retinal neurodegeneration. Diabetes Care 2007, 30:2902-2908.
42. Carrasco E., et al. Lowered cortistatin expression is an early event in the human diabetic retina and is associated with apoptosis and glial activation. Mol. Vis. 2008, 4:1496-1502.
43. Garcia-Ramírez M., et al. Interphotoreceptor retinoid-binding protein (IRBP) is downregulated at early stages of diabetic retinopathy. Diabetologia 2009, 52:2633-2641.
44. Valverde A.M., et al. Proapoptotic and survival signaling in the neuroretina at early stages of diabetic retinopathy. Mol. Vis. 2013, 19:47-53.
45. Di Leo M.A., et al. Spatial frequency-selective losses with pattern electroretinogram in type 1 (insulin-dependent) diabetic patients without retinopathy. Diabetologia 1990, 33:726-730.
46. Di Leo M.A., et al. Presence and further development of retinal dysfunction after 3-year follow up in IDDM patients without angiographically documented vasculopathy. Diabetologia 1994, 37:911-916.
47. Shirao Y., Kawasaki K. Electrical responses from diabetic retina. Prog. Retin. Eye Res. 1998, 17:59-76.
48. Ewing F.M., et al. Seeing beyond retinopathy in diabetes: electrophysiological and psychophysical abnormalities and alterations in vision. Endocr. Rev. 1998, 19:462-476.
49. Bearse M.A., et al. A multifocal electroretinogram model predicting the development of diabetic retinopathy. Prog. Retin. Eye Res. 2006, 25:425-448.
50. Bronson-Castain K.W., et al. Adolescents with Type 2 diabetes: early indications of focal retinal neuropathy, retinal thinning, and venular dilation. Retina 2009, 29:618-626.
51. Han Y., et al. Formulation and evaluation of a predictive model to identify the sites of future diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 2004, 45:4106-4112.
52. Harrison W.W., et al. Multifocal electroretinograms predict onset of diabetic retinopathy in adult patients with diabetes. Invest. Ophthalmol. Vis. Sci. 2011, 52:772-777.
53. Ng J.S., et al. Local diabetic retinopathy prediction by multifocal ERG delays over 3 years. Invest. Ophthalmol. Vis. Sci. 2008, 49:1622-1628.
54. Riva C.E., et al. Visually evoked hemodynamical response and assessment of neurovascular coupling in the optic nerve and retina. Prog. Retin. Eye Res. 2005, 24:183-215.
55. Formaz F., et al. Diffuse luminance flicker increases retinal vessel diameter in humans. Curr. Eye Res. 1997, 16:1252-1257.
56. Metea M.R., Newman E.A. Signalling within the neurovascular unit in the mammalian retina. Exp. Physiol. 2007, 92:635-640.
57. Artwell D., et al. Glial and neural control of brain blood flow. Nature 2010, 468:232-243.
58. Kur J., et al. Cellular and physiological mechanisms underlying blood flow regulation in the retina and choroid in health and disease. Prog. Retin. Eye Res. 2012, 31:377-406.
59. Buerk D.G., et al. Nitric oxide has a vasodilatory role in cat optic nerve head injury during flicker stimuli. Microvasc. Res. 1996, 52:13-26.
60. Dorner G.T., et al. Nitric oxide regulates retinal vascular tone in humans. Am. J. Physiol. Heart Circ. Physiol. 2003, 285:H631-H636.
61. Maenhaut N., et al. Control of retinal arterial tone by a paracrine retinal relaxing factor. Microcirculation 2007, 14:39-48.
62. Metea M.R., Newman E.A. Glial cells dilate and constrict blood vessels: a mechanism of neurovascular coupling. J. Neurosci. 2006, 26:2862-2870.
63. Wurm A., et al. Purinergic signaling involved in Müller cell function in the mammalian retina. Prog. Retin. Eye Res. 2011, 30:324-342.
64. Lecleire-Collet A., et al. Evaluation of retinal function flicker light-induced retinal vascular response in normotensive patients with diabetes without retinopathy. Invest. Ophthalmol. Vis. Sci. 2011, 52:2861-2867.
65. Tyberg M., et al. Electrophysiological studies in newly onset type 2 diabetes without visible vascular retinopathy. Doc. Ophthalmol. 2011, 123:193-198.
66. Nguyen T.T., et al. Flicker light-induced retinal vasodilation in diabetes and diabetic retinopathy. Diabetes Care 2009, 32:2075-2080.
67. Pemp B., et al. Reduced retinal vessel response to flicker stimulation but not exogenous nitric oxide in type 1 diabetes. Invest. Ophthalmol. Vis. Sci. 2009, 50:4029-4032.
68. Lasta M., et al. Neurovascular dysfunction precedes neural dysfunction in the retina of patients with type 1 diabetes. Invest. Ophthalmol. Vis. Sci. 2013, 30:842-847.
69. Antonetti D.A., et al. Diabetic retinopathy. N. Engl. J. Med. 2012, 366:1227-1239.
70. Lieth E., et al. Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy. Penn State Retina Research Group. Diabetes 1998, 47:815-820.
71. Lieth E., et al. Diabetes reduces glutamate oxidation and glutamine synthesis in the retina. The Penn State Retina Research Group. Exp. Eye Res. 2000, 70:723-730.
72. Kowluru R.A., et al. Retinal glutamate in diabetes and effect of antioxidants. Neurochem. Int. 2001, 38:385-390.
73. Ambati J., et al. Elevated gamma-aminobutyric acid, glutamate, and vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch. Ophthalmol. 1997, 115:1161-1166.
74. Pulido J.E., et al. A role for excitatory amino acids in diabetic eye disease. Exp. Diabetes Res. 2007, 2007:36150.
75. Ng Y.K., et al. Expression of glutamate receptors and calcium-binding proteins in the retina of streptozotocin-induced diabetic rats. Brain Res. 2004, 1018:66-72.
76. Santiago A.R., et al. Diabetes changes the levels of ionotropic glutamate receptors in the rat retina. Mol. Vis. 2009, 15:1620-1630.
77. Jarret S.G., et al. Mitochondrial DNA damage and its potential role in retinal degeneration. Prog. Retin. Eye Res. 2008, 27:596-607.
78. Kowluru R.A., Chan P.S. Oxidative stress and diabetic retinopathy. Exp. Diabetes Res. 2007, 2007:43603.
79. Giroti A.W., Kriska T. Role of hydroxiperoxides in photo-oxidative stress signalling. Antioxid. Redox Signal. 2004, 6:301-310.
80. Kowluru R., et al. Abnormalities of retinal metabolism in diabetes or galactosemia, II: comparison of gamma-glutamyl transpeptidase in retina and cerebral cortex, and effects of antioxidant therapy. Curr. Eye Res. 1994, 13:891-896.
81. Xiao C., et al. Physiological effects of superoxide dismutase on altered visual function of retinal ganglion cells in db/db mice. PLoS ONE 2012, 7:e30343.
82. Fukumoto M., et al. Vulnerability of the retinal microvasculature to oxidative stress: ion channel-dependent mechanisms. Am. J. Physiol. Cell Physiol. 2012, 302:C1413-C1420.
83. Li Q., Puro D.G. Diabetes-induced dysfunction of the glutamate transporter in retinal Müller cells. Invest. Ophthalmol. Vis. Sci. 2002, 43:3109-3116.
84. Osborne N.N., et al. Retinal ischemia: mechanisms of damage and potential therapeutic strategies. Prog. Retin. Eye Res. 2004, 23:91-147.
85. Kaur C., et al. Hypoxia-ischemia and retinal ganglion cell damage. Clin. Ophthalmol. 2008, 2:879-889.
86. Barnstable C.J., Tombran-Tink J. Neuroprotective and antiangiogenic actions of PEDF in the eye: molecular targets and therapeutic potential. Prog. Retin. Eye Res. 2004, 23:561-577.
87. Shen X., et al. Effect of pigment epithelium derived factor on the expression of glutamine synthetase in early phase of experimental diabetic retinopathy. Ocul. Immunol. Inflamm. 2011, 19:246-254.
88. Simó R., et al. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr. Diabetes Rev. 2006, 2:71-98.
89. Simó R., et al. Deficit of somatostatin-like immunoreactivity in the vitreous fluid of diabetic patients: possible role in the development of proliferative diabetic retinopathy. Diabetes Care 2002, 25:2282-2286.
90. Simó R., et al. Deficit of somatostatin in the vitreous fluid of patients with diabetic macular edema. Diabetes Care 2007, 30:725-727.
91. Hernández C., et al. Somatostatin molecular variants in the vitreous fluid: a comparative study between diabetic patients with proliferative diabetic retinopathy and nondiabetic control subjects. Diabetes Care 2005, 28:1941-1947.
92. Gonzalez-Fernandez F. Interphotoreceptor retinoid-binding protein - an old gene for new eyes. Vision Res. 2003, 43:3021-3036.
93. Wu Q., et al. Interphotoreceptor retinoid-binding protein is the physiologically relevant carrier that removes retinol from rod photoreceptor outer segments. Biochemistry 2007, 24:8669-8679.
94. Gonzalez-Fernandez F., Ghosh D. Focus on molecules: interphotoreceptor retinoid binding protein (IRBP). Exp. Eye Res. 2008, 86:169-170.
95. Liou G.I., et al. Early onset photoreceptor abnormalities induced by targeted disruption of the interphotoreceptor retinoid binding protein gene. J. Neurosci. 1998, 18:4511-4520.
96. Narfström K., et al. Reduced level of interphotoreceptor retinoid binding protein (IRBP), a possible cause for retinal degeneration in the Abyssinian cat. Cell Tissue Res. 1989, 257:631-639.
97. Wiggert B., et al. An early decreased in gene expression in Abyssinian cats homozygous for hereditary rod-cone degeneration. Cell Tissue Res. 1994, 278:291-298.
98. Ripps H., et al. The rhodopsin cycle is preserved in IRBP "knockout" mice despite abnormalities in retinal structure and function. Vis. Neurosci. 2000, 17:97-105.
99. den Hollander A., et al. A homozygous missense mutation in the IRBP gene (RBP3) associated with aurosomal recessive retinitis pigmentosa. Invest. Ophthalmol. Vis. Sci. 2009, 50:1864-1872.
100. Amin R.H., et al. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 1997, 38:36-47.
101. García-Ramírez M., et al. Expression of erythropoietin and its receptor in the human retina: a comparative study of diabetic and nondiabetic subjects. Diabetes Care 2008, 31:1189-1194.
102. Hernández C., et al. Erythropoietin is expressed in the human retina and it is highly elevated in the vitreous fluid of patients with diabetic macular edema. Diabetes Care 2006, 29:2028-2033.
103. García-Arumí J., et al. Vitreous levels of erythropoietin in patients with macular oedema secondary to retinal vein occlusions: a comparative study with diabetic macular oedema. Eye 2009, 23:1066-1071.
104. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 2004, 25:581-611.
105. Marneros A.G., et al. Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am. J. Pathol. 2005, 167:1451-1459.
106. Jin K.L., et al. Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:10242-10247.
107. Saint-Geniez M., et al. Endogenous VEGF is required for visual function: evidence for a survival role on Müller cells and photoreceptors. PLoS ONE 2008, 3:e3554.
108. Nishijima K., et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptative response ischemic injury. Am. J. Pathol. 2007, 171:53-67.
109. Bai Y., et al. Müller cell-derived VEGF is a significant contributor to retinal neovascularization. J. Pathol. 2009, 219:446-454.
110. Miki A., et al. Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells. J. Cell. Physiol. 2010, 224:262-272.
111. Becerra S.P., Amaral J. Erythropoietin: an endogenous retinal survival factor. N. Engl. J. Med. 2002, 347:1968-1970.
112. Rex T.S., et al. Neuroprotection of photoreceptors by direct delivery of erythropoietin to the retina of the retinal degeneration slow mouse. Exp. Eye Res. 2009, 89:735-740.
113. Shen J., et al. ERK- and Akt-dependent neuroprotection by erythropoietin (EPO) against glyoxal-AGEs via modulation of Bcl-xL, Bax, and BAD. Invest. Ophthalmol. Vis. Sci. 2010, 5:35-46.
114. Chen J., et al. Erythropoietin deficiency decreases vascular stability in mice. J. Clin. Invest. 2008, 118:526-533.
115. Grant M.B., et al. Erythropoietin: when liability becomes asset in neurovascular repair. J. Clin. Invest. 2008, 118:467-470.
116. Reiter C.E., et al. Diabetes reduces basal retinal insulin receptor signaling: reversal with systemic and local insulin. Diabetes 2006, 55:1148-1156.
117. Gordon W.C., et al. Mediator lipidomics in ophthalmology: targets for modulation in inflammation, neuroprotection and nerve regeneration. Curr. Eye Res. 2013, 38:995-1005.
118. Seki M., et al. Involved of brain-derived neurotrophic factor in early retinal neuropathy of streptozotocin-induced diabetes in rats: therapeutic potential of brain-derived neurotrophic factor for dopaminergic amacrine cells. Diabetes 2004, 53:2412-2419.
119. Wang N., et al. Upregulation of glutamate-aspartate transporter by glial cell line-derived neurotrophic factor ameliorates cell apoptosis in neural retina in streptozotocin-induced diabetic rats. CNS Neurosci. Ther. 2013, 10.1111/cns.12150.
120. Aizu Y., et al. Topical instillation of ciliary neurotrophic factor inhibits retinal degeneration in streptozotocin-induced diabetic rats. Neuroreport 2003, 14:2067-2071.
121. Ali T.K., et al. Diabetes-induced peroxynitrite impairs the balance of pro-nerve growth factor and nerve growth factor, and causes neurovascular injury. Diabetologia 2011, 54:657-668.
122. Hammes H.P., et al. Nerve growth factor prevents both neuroretinal programmed cell death and capillary pathology in experimental diabetes. Mol. Med. 1995, 1:527-534.
123. Blom J.J., et al. Inhibition of the adrenomedullin/nitric oxide signaling pathway in early diabetic retinopathy. J. Ocul. Biol. Dis. Infor. 2011, 4:70-82.
124. Joussen A.M., et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004, 18:1450-1452.
125. Kern T.S. Contributions of inflammatory processes to the development of early stages of diabetic retinopathy. Exp. Diabetes Res. 2007, 2007:95103.
126. Gerhardinger C., et al. Expression of acute-phase response proteins in retinal Müller cells in diabetes. Invest. Ophthalmol. Vis. Sci. 2005, 41:1971-1980.
127. Zhong Y., et al. Activation of endoplasmic reticulum stress by hyperglycemia is essential for Müller cell-derived inflammatory cytokine production in diabetes. Diabetes 2012, 61:492-504.
128. Zong H., et al. Hyperglycemia-induced proinflammatory responses by retinal Müller glia are regulated by receptor for advanced glycation end-products (RAGE). Diabetologia 2010, 53:2656-2666.
129. Berner A.K., et al. Protection against methylglyoxal-derived AGEs by regulation of glyoxalase 1 prevents retinal neuroglial and vasodegenerative pathology. Diabetologia 2012, 55:845-854.
130. Wilkinson-Berka J.L. Angiotensin and diabetic retinopathy. Int. J. Biochem. Cell Biol. 2006, 38:752-765.
131. Downie L.E., et al. AT1 receptor inhibition prevents astrocyte degeneration and restores vascular growth in oxygen-induced retinopathy. Glia 2008, 56:1076-1090.
132. Kurihara T., et al. Angiotensin II type 1 receptor signaling contributes to synaptophysin degradation and neuronal dysfunction in the diabetic retina. Diabetes 2008, 57:2191-2198.
133. Silva K.C., et al. Diabetic retinal neurodegeneration is associated with mitochondrial oxidative stress and is improved by an angiotensin receptor blocker in a model combining hypertension and diabetes. Diabetes 2009, 58:1382-1390.
134. Liu Y., et al. Pigment epithelium-derived factor (PEDF) peptide eye drops reduce inflammation, cell death and vascular leakage in diabetic retinopathy in Ins2(Akita) mice. Mol. Med. 2012, 20:1387-1401.
135. Luu C.D., et al. Correlation between retinal oscillatory potentials and retinal vascular caliber in type 2 diabetes. Invest. Ophthalmol. Vis. Sci. 2010, 51:482-486.
136. Shen W., et al. Retinal vascular changes after glial disruption in rats. J. Neurosci. Res. 2010, 88:1485-1499.
137. Mori K., et al. Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest. Ophthalmol. Vis. Sci. 2002, 43:2428-2434.
138. Chen L., et al. PEDF induces apoptosis in human endothelial cells by activating p38 MAP kinase dependent cleavage of multiple caspases. Biochem. Biophys. Res. Commun. 2006, 348:1288-1295.
139. Zhang S.X., et al. Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy. J. Mol. Endocrinol. 2006, 37:1-12.
140. Wilson S.H., et al. Modulation of retinal endothelial cell behaviour by insulin-like growth factor I and somatostatin analogues: implications for diabetic retinopathy. Growth Horm. IGF Res. 2001, 11:S53-S59.
141. Hellström A., et al. Reduced retinal vascularization in children with growth hormone deficiency. J. Clin. Endocrinol. Metab. 1999, 84:795-798.
142. Cervia D., et al. Vascular endothelial growth factor in the ischemic retina and its regulation by somatostatin. J. Neurochem. 2012, 120:818-829.
143. Mei S., et al. Mechanisms underlying somatostatin receptor 2 down-regulation of vascular endothelial growth factor expression in response to hypoxia in mouse retinal explants. J. Pathol. 2012, 226:519-533.
144. Hammes H.P., et al. Diabetic retinopathy: targeting vasoregression. Diabetes 2011, 60:9-16.
145. Feng Y., et al. Crosstalk in the retinal neurovascular unit-lessons for the diabetic retina. Exp. Clin. Endocrinol. Diabetes 2012, 120:199-201.
146. Loomans C.J., et al. Differentiation of bone marrow-derived endothelial progenitor cells is shifted into a proinflammatory phenotype by hyperglycemia. Mol. Med. 2009, 15:152-159.
147. Li Calzi S., et al. Endothelial progenitor dysfunction in the pathogenesis of diabetic retinopathy: treatment concept to correct associated deficits. EPMA J. 2010, 1:88-100.
148. Curtis T.M., et al. Müller glial dysfunction during diabetic retinopathy in rats is linked to accumulation of advanced glycation end-products and advanced lipoxidation end-products. Diabetologia 2011, 54:690-698.
149. Ye X., et al. Norrin, frizzled-4, and Lrp5 signaling in endothelial cells controls a genetic program for retinal vascularization. Cell 2009, 138:285-298.
150. Cheung S.S., et al. Selective over-expression of endothelin-1 in endothelial cells exacerbates inner retinal edema and neuronal death in ischemic retina. PLoS ONE 2011, 6:e26184.
151. Minton A.Z., et al. Endothelin B receptors contribute to retinal ganglion cell loss in a rat model of glaucoma. PLoS ONE 2012, 7:e43199.
152. Tonari M., et al. Blocking endothelin-B receptors rescues retinal ganglion cells from optic nerve injury through suppression of neuroinflammation. Invest. Ophthalmol. Vis. Sci. 2012, 8:3490-3500.
153. Mi X.S., et al. Progressive retinal degeneration in transgenic mice with overexpression of endothelin-1 in vascular endothelial cells. Invest. Ophthalmol. Vis. Sci. 2012, 53:4842-4851.
154. Nunes S., et al. Hierarchical cluster analysis identifies three different phenotypes of mild NPDR in patients with diabetes type 2, with different risks for development of CSME. Invest. Ophthalmol. Vis. Sci. 2013, 10.1167/iovs.13-11895.
155. Sasaki M., et al. Neurodegenerative influence of oxidative stress in the retina of a murine model of diabetes. Diabetologia 2010, 53:971-979.
156. Silva K.C., et al. Green tea is neuroprotective in diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 2013, 15:1325-1336.
157. Barba I., et al. Metabolic fingerprints of proliferative diabetic retinopathy: an 1H-NMR-based metabonomic approach using vitreous humor. Invest. Ophthalmol. Vis. Sci. 2010, 51:4416-4421.
158. Takita H., et al. Retinal neuroprotection against ischemic injury mediated by intraocular gene transfer of pigment epithelium-derived factor. Invest. Ophthalmol. Vis. Sci. 2003, 44:4497-4504.
159. Yoshida Y., et al. Protective role of pigment epithelium-derived factor (PEDF) in early phase of experimental diabetic retinopathy. Diabetes Metab. Res. Rev. 2009, 25:678-686.
160. Kiagiadaki F., et al. Activation of somatostatin receptor (sst 5) protects the rat retina from AMPA-induced neurotoxicity. Neuropharmacology 2010, 58:297-303.
161. Gong Y., et al. Protective effect of adeno-associated virus mediated brain-derived neurotrophic factor expression on retinal ganglion cells in diabetic rats. Cell. Mol. Neurobiol. 2012, 32:467-475. [Epub ahead of print, PMID: 22297541].
162. Zhang J., et al. Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes. Invest. Ophthalmol. Vis. Sci. 2008, 49:732-742.
163. Wang Q., et al. Long-term treatment with suberythropoietic Epo is vaso- and neuroprotective in experimental diabetic retinopathy. Cell. Physiol. Biochem. 2011, 27:769-782.
164. McVicar C.M., et al. Intervention with an erythropoietin-derived peptide protects against neuroglial and vascular degeneration during diabetic retinopathy. Diabetes 2011, 60:2995-3005.
165. Eljarrat-Binstock E., et al. New techniques for drug delivery to the posterior eye segment. Pharm. Res. 2010, 27:530-543.
166. Dong C.J., et al. Alpha 2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity. Invest. Ophthalmol. Vis. Sci. 2008, 49:4515-4522.
167. Saylor M., et al. Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review. Arch. Ophthalmol. 2009, 127:402-406.
168. Lambiase A., et al. Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: implications for glaucoma. Proc. Natl. Acad. Sci. U.S.A. 2008, 106:13469-13474.
169. Fort P.E., et al. Differential roles of hyperglycemia and hypoinsulinemia in diabetes induced retinal cell death: evidence for retinal insulin resistance. PLoS ONE 2011, 6:e26498.
170. Hernández C., et al. Topical administration of somatostatin prevents retinal neurodegeneration in experimental diabetes. Diabetes 2013, 62:2569-2578.
171. Aiello L.P. Targeting intraocular neovascularization and edema - one drop at a time. N. Engl. J. Med. 2008, 359:967-969.
172. Simó R., et al. The retinal pigment epithelium: something more than a constituent of the blood-retinal barrier - implications for the pathogenesis of diabetic retinopathy. J. Biomed. Biotechnol. 2010, 2010:190724.
173. Arden G.B., et al. Spare the rod and spoil the eye. Br. J. Ophthalmol. 2005, 89:764-769.
174. Kergoat H., et al. RGC sensitivity to mild systemic hypoxia. Invest. Ophthalmol. Vis. Sci. 2006, 47:5423-5427.
175. Mizutani M., et al. Müller cell changes in human diabetic retinopathy. Diabetes 1998, 47:445-449.
176. Bringmann A., Wiedemann P. Müller glial cells in retinal disease. Ophthalmologica 2012, 227:1-19.
177. Zeng H.Y., et al. Microglial activation in human diabetic retinopathy. Arch. Ophthalmol. 2008, 126:227-232.
178. Omri S., et al. Microglia/macrophages migrate through retinal epithelium barrier by a transcellular route in diabetic retinopathy: role of PKCζ in the Goto Kakizaki rat model. Am. J. Pathol. 2011, 179:942-953.